ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders

Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,644 · see citing works

Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium

Séguéla, P., Wadiche, J. I., Dineley‐Miller, K., Dani, J., & Jw, P. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-02-00596.1993 · Cited by 1,471 · see citing works

Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins

Karlin, A., & Akabas, M. H. (1995) · Neuron · doi:10.1016/0896-6273(95)90004-7 · Cited by 622 · see citing works

Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal alpha 7 nicotinic receptor.

Bertrand, D., Galzi, J., Devillers‐Thiéry, A., Bertrand, S., & Changeux, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.15.6971 · Cited by 390 · see citing works

Nicotinic receptor subtypes and cognitive function

Levin, E. D. (2002) · Journal of Neurobiology · doi:10.1002/neu.10151 · Cited by 354 · see citing works

Nicotine and sympathetic neurotransmission

Haass, M., & K�bler, W. (1997) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00053022 · Cited by 298 · see citing works

Nicotinic receptor function: new perspectives from knockout mice

Cordero‐Erausquin, M., Marubio, L. M., Klink, R., & Changeux, J. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01489-9 · Cited by 293 · see citing works

Comparative pharmacology of rat and human α7 nAChR conducted with net charge analysis

Papke, R. L., & Porter Papke, J. K. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704833 · Cited by 249 · see citing works

Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain.

Bertrand, D., Devillers‐Thiéry, A., Revah, F., Galzi, J., Hussy, N., Mulle, C., Bertrand, S., Ballivet, M., & Changeux, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1261 · Cited by 241 · see citing works

α-Bungarotoxin-Sensitive Nicotinic Receptors Indirectly Modulate [3H]Dopamine Release in Rat Striatal Slices via Glutamate Release

Kaiser, S., & Wonnacott, S. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.2.312 · Cited by 218 · see citing works

Neuronal nicotinic receptors : pharmacology and therapeutic opportunities

Arnerić, S. P., & Brioni, J. D. (1999) · Wiley-Liss eBooks · Cited by 202 · see citing works

Direct evidence that release‐stimulating α7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals

Marchi, M., Risso, F., Viola, C., Cavazzani, P., & Raiteri, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00805.x · Cited by 191 · see citing works

Presynaptic Nicotinic Receptors Facilitate Monoaminergic Transmission

Li, X., Rainnie, D. G., McCarley, R. W., & Greene, R. W. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01904.1998 · Cited by 176 · see citing works

Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys

Buccafusco, J. J., & Jackson, W. J. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90102-p · Cited by 164 · see citing works

Genetics of nicotine response in four inbred strains of mice

Marks, M. J., Burch, J. B., & Collins, A. C. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21452-5 · Cited by 140 · see citing works

Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.

Wernicke, J. F., & Kratochvil, C. J. (2002) · PubMed · Cited by 129 · see citing works

Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors

Girod, R., Barazangi, N., McGehee, D., & Role, L. W. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00145-3 · Cited by 122 · see citing works

Nicotinic acetylcholine receptors in autonomic ganglia

Skok, V. I. (2002) · Autonomic Neuroscience · doi:10.1016/s1566-0702(01)00386-1 · Cited by 116 · see citing works

Alzheimer Disease: from Molecular Biology to Therapy

Giacobini, E. (1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)85593-x · Cited by 115 · see citing works

Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes.

Marks, M. J., Farnham, D. A., Grady, S. R., & Collins, A. C. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10175-4 · Cited by 112 · see citing works

Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists

Briggs, C. A., & McKenna, D. G. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00110-5 · Cited by 108 · see citing works

Effects of lobeline, a nicotinic receptor agonist, on learning and memory

Decker, M. W., Majchrzak, M. J., & Arnerić, S. P. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90508-q · Cited by 107 · see citing works

In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418

Donnelly‐Roberts, D. L., Xue, I. C., Arnerić, S. P., & Sullivan, J. P. (1996) · Brain Research · doi:10.1016/0006-8993(96)00063-7 · Cited by 103 · see citing works

Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys

Prendergast, M., Jackson, W. J., Terry, A. V., Decker, M. W., Arnerić, S. P., & Buccafusco, J. J. (1998) · Psychopharmacology · doi:10.1007/s002130050538 · Cited by 99 · see citing works

Barium permeability of neuronal nicotinic receptor alpha 7 expressed in Xenopus oocytes

Sands, S. B., Costa, A. C., & Patrick, J. (1993) · Biophysical Journal · doi:10.1016/s0006-3495(93)81296-7 · Cited by 91 · see citing works

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys

Decker, M. W., Bannon, A. W., Curzon, P., Gunther, K. L., Brioni, J. D., Holladay, M. W., Lin, N.-H., Li, Y., Daanen, J. F., Buccafusco, J. J., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37015-6 · Cited by 88 · see citing works

Novel treatments for attention-deficit/hyperactivity disorder in children.

Spencer, T. J., Biederman, J., Wilens, T. E., & Faraone, S. V. (2002) · PubMed · Cited by 83 · see citing works

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties

Sullivan, J. P., Donnelly‐Roberts, D. L., Briggs, C. A., Anderson, D. J., Gopalakrishnan, M., Xue, I. C., Piattoni-Kaplan, M., Molinari, E. J., Campbell, J. E., McKenna, D. G., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37014-4 · Cited by 79 · see citing works

Nicotinic systems in central nervous systems disease: degenerative disorders and beyond

NEWHOUSE, P. A., & Kelton, M. (2000) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(99)00047-3 · Cited by 75 · see citing works

Fractional Ca2+ current through human neuronal α7 nicotinic acetylcholine receptors

Fucile, S., Renzi, M., Lax, P., & Eusebi, F. (2003) · Cell Calcium · doi:10.1016/s0143-4160(03)00071-x · Cited by 71 · see citing works

Structure−Activity Studies on 2-Methyl-3-(2(<i>S</i>)-pyrrolidinylmethoxy)pyridine (ABT-089):  An Orally Bioavailable 3-Pyridyl Ether Nicotinic Acetylcholine Receptor Ligand with Cognition-Enhancing Properties

Lin, N.-H., Gunn, D. E., Ryther, K. B., Garvey, D. S., Donnelly-Roberts, D. L., Decker, M. W., Brioni, J. D., Buckley, M. J., Rodrigues, A. D., Marsh, K. G., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960233u · Cited by 67 · see citing works

Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line.

Lukas, R. J. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38126-7 · Cited by 65 · see citing works

Characterization of Curaremimetic Neurotoxin Binding Sites on Membrane Fractions Derived from the Human Medulloblastoma Clonal Line, TE671

Lukas, R. J. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb08516.x · Cited by 62 · see citing works

Evaluation of memantine for the treatment of Alzheimer’s disease

Ferris, S. H. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.12.2305 · Cited by 60 · see citing works

Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of α7 receptors

Tucci, S. A., Genn, R. F., & File, S. E. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(02)00391-x · Cited by 59 · see citing works

Positive Feedback Modulation of Acetylcholine Release from Isolated Rat Superior Cervical Ganglion

Liang, S., & Vizi, E. S. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36435-3 · Cited by 43 · see citing works

Nicotinic acetylcholine receptors in the rat and primate nucleus tractus solitarius and on rat and human inferior vagal (nodose) ganglia: evidence from in vivo microdialysis and [125I]α-bungarotoxin autoradiography

Ashworth-Preece, M. A., Jarrott, B., & Lawrence, A. J. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00476-4 · Cited by 43 · see citing works

Local alpha-bungarotoxin-sensitive nicotinic receptors modulate hippocampal norepinephrine release by systemic nicotine.

Fu, Y., Matta, S. G., & Sharp, B. M. (1999) · PubMed · Cited by 29 · see citing works

Gain of function mutation of the α7 nicotinic receptor: distinct pharmacology of the human α7V274T variant

Briggs, C. A., McKenna, D. G., Monteggia, L. M., Touma, E., Roch, J., Arnerić, S. P., Gopalakrishnan, M., & Sullivan, J. P. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00909-1 · Cited by 28 · see citing works

Long-Lasting Facilitation of 4-Amino-n-[2,3-3H]butyric Acid ([3H]GABA) Release from Rat Hippocampal Slices by Nicotinic Receptor Activation

Köfalvi, A., Sperlaágh, B., Zelles, T., & Vizi, E. S. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38926-8 · Cited by 21 · see citing works

Therapeutic approaches to the treatment of Alzheimer's disease

Yamada, K., & Toshitaka, N. (2002) · Drugs of today · doi:10.1358/dot.2002.38.9.696538 · Cited by 15 · see citing works

Local α-Bungarotoxin-Sensitive Nicotinic Receptors Modulate Hippocampal Norepinephrine Release by Systemic Nicotine

Fu, Y., Matta, S. G., & Sharp, B. M. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38115-7 · Cited by 13 · see citing works

The nicotinic modulation of [3H]D-aspartate outflow in primary cultures of rat neocortical neurons: effect of acute and long term nicotine treatment

Beani, L., Antonelli, T., Tomasini, M. C., Marani, L., & Bianchi, C. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00155-6 · Cited by 8 · see citing works

ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action

Arnerić, S. P., Bannon, A. W., Brioni, J. D., Briggs, C. A., Decker, M. W., Holladay, M. W., Marsh, K. C., Donnelly‐Roberts, D. L., Sullivan, J. P., Williams, M. J., et al. (1997) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-4116-4_42 · Cited by 5 · see citing works

Neuronal Nicotinic Acetylcholine Receptors: Structural Revelations, Target Identifications, and Therapeutic Inspirations

Jensen, A. A., Frølund, B., Liljefors, T., & Krogsgaard‐Larsen, P. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040219e · Cited by 541 · see citing works

A cog in cognition: How the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits

Leiser, S. C., Bowlby, M. R., Comery, T. A., & Dunlop, J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.009 · Cited by 166 · see citing works

Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Focus on cognition

Wilens, T. E., & Decker, M. W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.002 · Cited by 164 · see citing works

Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study

Marfo, J. T., Fujioka, K., Ikenaka, Y., Nakayama, S. M. M., Mizukawa, H., Aoyama, Y., Ishizuka, M., & Taira, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142172 · Cited by 164 · see citing works

Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential

Romanelli, M. N., Gratteri, P., Guandalini, L., Martini, E., Bonaccini, C., & Gualtieri, F. (2007) · ChemMedChem · doi:10.1002/cmdc.200600207 · Cited by 164 · see citing works

Cholinergic Control over Attention in Rats Prone to Attribute Incentive Salience to Reward Cues

Paolone, G., Angelakos, C. C., Meyer, P., Robinson, T. E., & Sarter, M. F. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.0709-13.2013 · Cited by 142 · see citing works

Prefrontal β2 Subunit-Containing and α7 Nicotinic Acetylcholine Receptors Differentially Control Glutamatergic and Cholinergic Signaling

Parikh, V., Ji, J., Decker, M. W., & Sarter, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5712-09.2010 · Cited by 133 · see citing works

Animal models of Alzheimer disease: historical pitfalls and a path forward

Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132 · see citing works

Glutamatergic Contributions to Nicotinic Acetylcholine Receptor Agonist-Evoked Cholinergic Transients in the Prefrontal Cortex

Parikh, V., Man, K., Decker, M. W., & Sarter, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5251-07.2008 · Cited by 127 · see citing works

ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study

Wilens, T. E., Verlinden, M. H., Adler, L. A., Wozniak, P. J., & West, S. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.029 · Cited by 123 · see citing works

Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer’s Dementia: An Update

Hoskin, J. L., Al-Hasan, Y. M., & Sabbagh, M. N. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty116 · Cited by 123 · see citing works

Negative affective states and cognitive impairments in nicotine dependence

Hall, F. S., Der‐Avakian, A., Gould, T. J., Markou, A., Shoaib, M. C., & Young, J. W. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.06.004 · Cited by 104 · see citing works

Review on anti-alzheimer drug development: approaches, challenges and perspectives

Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 63 · see citing works

An update on pharmacological approaches to neurodegenerative diseases

Scatena, R., Martorana, G. E., Bottoni, P., Botta, G., Pastore, P., & Giardina, B. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.1.59 · Cited by 60 · see citing works

Preclinical research into cognition enhancers

Sarter, M. F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.09.004 · Cited by 56 · see citing works

Donepezil for Alzheimer’s disease

Benjamin, B., & Burns, A. S. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1243 · Cited by 55 · see citing works

The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model

Ostrovskaya, R. U., Алексеевна, Г. М., Bobkova, N. A., Sewell, R. D. E., Гудашева, Т. А., Samokhin, A. N., Seredinin, S. B., Noppe, W., Sherstnev, V. V., & Morozova‐Roche, L. A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106071335 · Cited by 53 · see citing works

Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

Apostol, G., Abi‐Saab, W., Kratochvil, C. J., Adler, L. A., Robieson, W., Gault, L. M., Pritchett, Y., Feifel, D., Collins, M. A., & Saltarelli, M. D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2393-2 · Cited by 52 · see citing works

Brain Myelination in Prevalent Neuropsychiatric Developmental Disorders: Primary and Comorbid Addiction

Flaherty, L. T. (2013) · Routledge eBooks · doi:10.4324/9780203780589-9 · Cited by 49 · see citing works

Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery

Terry, A. V., & Callahan, P. M. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty166 · Cited by 47 · see citing works

Synthesis and Structure−Activity Relationship Studies of 3,6-Diazabicyclo[3.2.0]heptanes as Novel α4β2 Nicotinic Acetylcholine Receptor Selective Agonists

Ji, J., Schrimpf, M. R., Sippy, K. B., Bunnelle, W. H., Li, T., Anderson, D. J., Faltynek, C. R., Surowy, C. S., Dyhring, T., Ahring, P. K., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070755h · Cited by 46 · see citing works

Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats

Skoubis, P. D., Hradil, V. P., Chin, C.-L., Luo, Y., Fox, G. B., & McGaraughty, S. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.08.072 · Cited by 46 · see citing works

Progress in the development of new drugs in Alzheimer's disease

Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. J. (2011) · The journal of nutrition health & aging · doi:10.1007/s12603-011-0012-x · Cited by 41 · see citing works

Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders

Terry, A. V., Callahan, P. M., & Hernandez, C. M. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.07.027 · Cited by 40 · see citing works

High Throughput Electrophysiology with Xenopus Oocytes

Smith‐Maxwell, C. J., & Papke, R. L. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709787047975 · Cited by 40 · see citing works

Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors

Letchworth, S. R., & Whiteaker, P. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.022 · Cited by 39 · see citing works

α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain

Nirogi, R. V. S., Goura, V., Abraham, R., & Jayarajan, P. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.04.021 · Cited by 39 · see citing works

An electrophysiological characterization of naturally occurring tobacco alkaloids and their action on human α4β2 and α7 nicotinic acetylcholine receptors

Alijevic, O., McHugh, D., Rufener, L., Mazurov, A. A., Hoeng, J., & Peitsch, M. C. (2019) · Phytochemistry · doi:10.1016/j.phytochem.2019.112187 · Cited by 35 · see citing works

Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials

Wilens, T. E., Gault, L. M., Childress, A. C., Kratochvil, C. J., Bensman, L., Hall, C. M., Olson, E., Robieson, W., Garimella, T. S., Abi‐Saab, W., et al. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.10.001 · Cited by 34 · see citing works

Selectivity of ABT-089 for α4β2* and α6β2* nicotinic acetylcholine receptors in brain

Marks, M. J., Wageman, C. R., Grady, S. R., Gopalakrishnan, M., & Briggs, C. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.022 · Cited by 30 · see citing works

The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats

Paterson, N. E., Min, W., Hackett, A., Lowe, D., Hanania, T., Caldarone, B. J., & Ghavami, A. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.037 · Cited by 30 · see citing works

Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant α4β2 nicotinic acetylcholine receptor potentiators

Albrecht, B. K., Berry, V. M., Boezio, A. A., Cao, L., Clarkin, K., Guo, W., Harmange, J.-C., Hierl, M., Huang, L., Janosky, B., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.080 · Cited by 29 · see citing works

Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors

Yohn, N. L., Turner, J. R., & Blendy, J. A. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211706 · Cited by 28 · see citing works

Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease

Lenz, R. A., Pritchett, Y., Berry, S. M., Llano, D. A., Han, S., Berry, D. A., Sadowsky, C., Abi‐Saab, W., & Saltarelli, M. D. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000093 · Cited by 28 · see citing works

Lack of RIC-3 congruence with β2 subunit-containing nicotinic acetylcholine receptors in bipolar disorder

Severance, E. G., & Yolken, R. H. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.06.008 · Cited by 25 · see citing works

Chemistry and Pharmacological Characterization of Novel Nitrogen Analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(Azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

Liu, J., Eaton, J. B., Caldarone, B. J., Lukas, R. J., & Kozikowski, A. P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100765u · Cited by 23 · see citing works

Octahydropyrrolo[3,4-c]pyrrole: A Diamine Scaffold for Construction of Either α4β2 or α7-Selective Nicotinic Acetylcholine Receptor (nAChR) Ligands. Substitutions that Switch Subtype Selectivity

Bunnelle, W. H., Tietje, K. R., Frost, J. M., Peters, D., Ji, J., Li, T., Scanio, M. J. C., Shi, L., Anderson, D. J., Dyhring, T., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900249k · Cited by 22 · see citing works

Neuronal Nicotinic Acetylcholine Receptor Modulators: Recent Advances and Therapeutic Potential

Breining, S. R., Mazurov, A. A., & Miller, C. H. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40001-9 · Cited by 21 · see citing works

Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease

Lindner, M. D., McArthur, R. A., Deadwyler, S. A., Hampson, R. E., & Tariot, P. N. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00016-3 · Cited by 20 · see citing works

Dissociation of nicotinic α7 and α4/β2 sub-receptor agonists for enhancing learning and attentional filtering in nonhuman primates

Azimi, M., Oemisch, M., & Womelsdorf, T. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05430-w · Cited by 19 · see citing works

Mouse models for studying genetic influences on factors determining smoking cessation success in humans

Hall, F. S., Markou, A., Levin, E. D., & Uhl, G. R. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06415.x · Cited by 18 · see citing works

A Systematic Review on Drugs Acting as Nicotinic Acetylcholine Receptor Agonists in the Treatment of Dementia

Crestini, A., Carbone, E., Rivabene, R., Ancidoni, A., Rosa, P., Tata, A. M., Fabrizi, E., Locuratolo, N., Vanacore, N., Lacorte, E., et al. (2024) · Cells · doi:10.3390/cells13030237 · Cited by 17 · see citing works

Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder

Fleisher, C., & McGough, J. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.934806 · Cited by 14 · see citing works

ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice

Yildirim, E., Connor, D. A., & Gould, T. J. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000111 · Cited by 13 · see citing works

Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats

Lee, A. M., Arreola, A. C., Kimmey, B. A., & Schmidt, H. D. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.016 · Cited by 13 · see citing works

Pharmacokinetic Modeling and [123I]5-IA-85380 Single Photon Emission Computed Tomography Imaging in Baboons: Optimization of Dosing Regimen for ABT-089

Chin, C., Carr, R. A., Llano, D. A., Barret, O., Xu, H., Batis, J., Koren, A. O., Seibyl, J. P., Marsh, K. C., Tamagnan, G. D., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173609 · Cited by 10 · see citing works

Pozanicline for the treatment of attention-deficit/hyperactivity disorder

Childress, A. C., & Sallee, F. R. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.956078 · Cited by 10 · see citing works

Recent advances in the treatment of tobacco dependence

Anthenelli, R. M. (2005) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2005.08.014 · Cited by 10 · see citing works

Desformylflustrabromine, a positive allosteric modulator of α4β2-containing nicotinic acetylcholine receptors, enhances cognition in rats

Nikiforuk, A., Litwa, E., Krawczyk, M., Popik, P., & Arias, H. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00092-4 · Cited by 9 · see citing works

Psicofarmacología de la nicotina y conducta adictiva

Molero‐Chamizo, A., & Muñoz-Negro, J. E. (2005) · Trastornos Adictivos · doi:10.1016/s1575-0973(05)74521-9 · Cited by 8 · see citing works

The potential of neuronal nicotinic acetylcholine receptor agonists for treating CNS conditions

Decker, M. W., Gopalakrishnan, M., & Meyer, M. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1027 · Cited by 7 · see citing works

Structure–Activity Studies of Diazabicyclo[3.3.0]octane-Substituted Pyrazines and Pyridines as Potent α4β2 Nicotinic Acetylcholine Receptor Ligands

Scanio, M. J. C., Shi, L., Bunnelle, W. H., Anderson, D. J., Helfrich, R. J., Malysz, J., Thorin‐Hagene, K., Handel, C. E. V., Marsh, K. C., Lee, C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201045m · Cited by 6 · see citing works

Progress in the development of new drugs in Alzheimer’s disease

Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. J. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0103-0 · Cited by 3 · see citing works

Anabasine as a precursor for the synthesis of potential agonists of neuronal acetylcholine receptors

Shults, E. E., Мусина, Л. А., Adekenov, S. M., & Толстиков, Г. А. (2007) · Doklady Chemistry · doi:10.1134/s0012500807030019 · Cited by 3 · see citing works

Mapping of the interaction sites of galanthamine: a quantitative analysis through pairwise potentials and quantum chemistry

Galland, N., Koné, S., & Questel, J. L. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9602-x · Cited by 3 · see citing works

Synthesis of hybrid compounds derived from diterpene alkaloid lappaconitine

Romanov, V. E., Shults, E. E., Shakirov, M. M., & Толстиков, Г. А. (2010) · Doklady Chemistry · doi:10.1134/s0012500810010076 · Cited by 3 · see citing works

Nouvelles thérapeutiques dans la maladie d’Alzheimer: vers un traitement visant à ralentir la progression de la maladie

Piau, A., Hein, C., Nourhashémi, F., & Vellas, B. J. (2009) · Les cahiers de l année gérontologique · doi:10.1007/s12612-009-0013-0 · Cited by 2 · see citing works

Synthetic transformations of isoquinoline alkaloids. Synthesis of new dihydrothebaine-hydroquinone derivatives

Bauman, V. T., Shults, E. E., Shakirov, M. M., & Толстиков, Г. А. (2007) · Russian Chemical Bulletin · doi:10.1007/s11172-007-0190-1 · Cited by 2 · see citing works

The Heterogeneous Kinetic Origins of the Binding Properties of Orthosteric Ligands at Heteromeric Nicotinic Acetylcholine Receptors

Holmgård, D. S. G., Zhou, L., Kristensen, J. L., & Jensen, A. A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00089 · Cited by 1 · see citing works

Nicotinic Acetylcholine Receptor Modulators

Mazurov, A. A., & Yohannes, D. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_56 · Cited by 1 · see citing works

Drug Development and Alzheimer's Disease

Delrieu, J., Piau, A., & Vellas, B. J. (2012) · Wiley eBooks · doi:10.1002/9781119952930.ch78 · Cited by 1 · see citing works

Pharmacological Evaluation of Choline on α4β2 Neuronal Nicotinic Acetylcholine Receptors

Bizimana, L. (2015) · The Sydney eScholarship Repository (The University of Sydney)

Stereochemical Synthesis of Ring E Analogs of Methyllycaconitine and 4,5-Disubstituted Oxazolidinones

Orac, C. M. (2009) · OhioLink ETD Center (Ohio Library and Information Network)

"Principal Component Analysis and the Cumulative Gait Index: Translational Tools to Assess Gait Impairments in Rats with Olivocerebellar Ataxia"

Lambert, C. S. (2015) · Digital Commons - University of South Florida (University of South Florida)

The Influence of Alpha7 and Alpha4 Beta2 Nicotinic Receptor Agonists on Feature Based Reversal Learning in Macaque Monkeys

Azimi, M. (2017) · YorkSpace (York University)

Cognition

Hudkins, R. L., Marino, M. J., & Williams, M. (2010) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc242

Drug development and Alzheimer's disease

Delrieu, J., & Vellas, B. J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch68

Cortical mechanisms of comorbidity between pain sensitization and attention-deficit/hyperactivity disorder (ADHD) in a mouse model

Nehme, S. B. S. (2024) · theses.fr (ABES) · doi:10.70675/7ad70482z0961z4eebzbc86z84355cab1f1d

BindingDB Entry 50041858: Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) asa4ß2-nicotinic acetylcholine receptor-selective partial agonists.

BindingDB (2013) · UC San Diego · doi:10.7270/q25b03rq

BindingDB Entry 50027166: Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators.

BindingDB (2010) · UC San Diego · doi:10.7270/q2sx6d26

BindingDB Entry 50037517: Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.

BindingDB (2012) · UC San Diego · doi:10.7270/q29w0g79

BindingDB Entry 50004601: Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as potent α4β2 nicotinic acetylcholine receptor ligands.

BindingDB (2020) · UC San Diego · doi:10.7270/q20z7646

BindingDB Entry 50038852: Octahydropyrrolo[3,4-c]pyrrole: a diamine scaffold for construction of either alpha4beta2 or alpha7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity.

BindingDB (2012) · UC San Diego · doi:10.7270/q2gt5p3r

BindingDB Entry 50023329: The Heterogeneous Kinetic Origins of the Binding Properties of Orthosteric Ligands at Heteromeric Nicotinic Acetylcholine Receptors.

BindingDB (2026) · UC San Diego · doi:10.7270/q2dr31cd

BindingDB Entry 50041515: Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists.

BindingDB (2013) · UC San Diego · doi:10.7270/q2f190zz

ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties

Sullivan, J. P., Donnelly‐Roberts, D. L., Briggs, C. A., Anderson, D. J., Gopalakrishnan, M., Xue, I. C., Piattoni-Kaplan, M., Molinari, E. J., Campbell, J. E., McKenna, D. G., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37014-4 · Cited by 79 · see citing works

ABT-089 [3-(2(S)-pyrrolidinylmethoxy)-2-methyl-pyridine]: An orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety

Arnerić, S. P., Campbell, J. E., Carroll, S., Daanen, J. F., Holladay, M. W., Johnson, P. M., Lin, N., Marsh, K. C., Peterson, B., Qui, Y., et al. (1997) · Drug Development Research · doi:10.1002/(sici)1098-2299(199705)41:1 · Cited by 13 · see citing works

O4‐04‐04: ABT‐089 demonstrates efficacy in a human model of cognition and good tolerability in subjects with Alzheimer's disease taking acetylcholinesterase inhibitors

Lenz, R. A., Garimella, T. S., Dutta, S., Locke, C. S., Baker, J. D., Wesnes, K. A., Maruff, P. T., Abi‐Saab, W., & Saltarelli, M. D. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.543 · Cited by 3 · see citing works

Selectivity of ABT-089 for α4β2* and α6β2* nicotinic acetylcholine receptors in brain

Marks, M. J., Wageman, C. R., Grady, S. R., Gopalakrishnan, M., & Briggs, C. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.022 · Cited by 30 · see citing works

Progress in the development of potent and selective cholinergic channel modulators (ChCMs)

Holladay, M. W., Lin, N., Sullivan, J. P., Donnelly‐Roberts, D. L., Decker, M. W., Brioni, J. D., Ferrero, J. L., Rodrigues, A. D., Marsh, K. G., Buccafusco, J. G., et al. (1997) · Pharmacochemistry library · doi:10.1016/s0165-7208(97)80059-1